| Literature DB >> 27239027 |
In Young Choi1, HoTae Lim1, Kenneth Estrellas2, Jyothi Mula3, Tatiana V Cohen3, Yuanfan Zhang2, Christopher J Donnelly4, Jean-Philippe Richard5, Yong Jun Kim6, Hyesoo Kim7, Yasuhiro Kazuki8, Mitsuo Oshimura9, Hongmei Lisa Li10, Akitsu Hotta11, Jeffrey Rothstein12, Nicholas Maragakis5, Kathryn R Wagner13, Gabsang Lee14.
Abstract
Duchenne muscular dystrophy (DMD) remains an intractable genetic disease. Althogh there are several animal models of DMD, there is no human cell model that carries patient-specific DYSTROPHIN mutations. Here, we present a human DMD model using human induced pluripotent stem cells (hiPSCs). Our model reveals concordant disease-related phenotypes with patient-dependent variation, which are partially reversed by genetic and pharmacological approaches. Our "chemical-compound-based" strategy successfully directs hiPSCs into expandable myoblasts, which exhibit a myogenic transcriptional program, forming striated contractile myofibers and participating in muscle regeneration in vivo. DMD-hiPSC-derived myoblasts show disease-related phenotypes with patient-to-patient variability, including aberrant expression of inflammation or immune-response genes and collagens, increased BMP/TGFβ signaling, and reduced fusion competence. Furthermore, by genetic correction and pharmacological "dual-SMAD" inhibition, the DMD-hiPSC-derived myoblasts and genetically corrected isogenic myoblasts form "rescued" multi-nucleated myotubes. In conclusion, our findings demonstrate the feasibility of establishing a human "DMD-in-a-dish" model using hiPSC-based disease modeling.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27239027 DOI: 10.1016/j.celrep.2016.05.016
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423